Babcock & Wilcox was worth $3.7 billion as one company. They split into two pieces. Combined value of the pieces: $6 billion. They created $2.3 billion of value by doing LESS.
How does that make sense?
It makes sense because sometimes a company’s parts are worth more than the whole. This is the conglomerate discount — and fixing it is one of the most reliable ways to create shareholder value.
But BWXT’s story doesn’t end with the spinoff. After separating, the CEO was hired to be a “hunter, not a farmer.” He bet $500 million on nuclear medicine — a market BWXT had never been in. Analysts panicked. The stock stagnated for three years. Then it tripled.
This is the story of why companies break apart, how to value the pieces, and what happens when a stable company decides to bet on growth. It’s also the capstone of everything we’ve learned — strategy analysis, financial ratios, forecasting, valuation, and investor communication all come together.
- You want to understand why companies spin off divisions — and when it creates value
- You want to learn sum-of-the-parts valuation and “what’s in the price” analysis
- You want to see how CEOs communicate strategy to skeptical investors
Imagine a restaurant that serves sushi, pizza, and tacos. Individually, each concept might thrive as a focused restaurant. Together, the menu confuses customers, the kitchen is chaotic, and no one knows what this place actually is.
That’s the conglomerate discount — when a company’s diverse parts are worth more separately than together. And fixing it is one of the most reliable ways to create shareholder value.
Two Ways Companies Transform
Companies transform in two fundamental directions:
- Diversification — developing new business lines or acquiring companies in new sectors. “We’ll do more things.”
- Divestiture — selling or spinning off parts of the business. “We’ll do fewer things, better.”
What motivates companies to diversify in the first place? Three common drivers:
- Technological advances — companies need to keep pace to stay competitive. Amazon diversified into cloud services (AWS), which became its most profitable division, even as it pursued online retail.
- Increasing customers’ willingness to pay — developing new products, improving existing ones, or changing how they interact with customers to capture more value.
- Environmental and social changes — a growing number of businesses transform to invest in green technologies. The energy giant TotalEnergies made strategic investments in alternative energy to reduce its dependence on fossil fuels.
Diversification also reduces risk by spreading investments across unrelated markets. But eventually, companies end up with business lines that need very different strategies, capital, and management focus — and that’s when divestitures happen, streamlining operations and refocusing on the core businesses that have become most promising.
Corporate divestitures come in several flavors: sales of equity stakes greater than 50%, business unit sales, asset sales, and public-ownership transactions. The most common public divestiture is the spinoff — where a multi-business company sells off one or more of its activities as separate independent companies.
The Fundamental Logic Behind a Split
The logic is simple: the value of at least one business unit is being held back by the other. Either you’re divesting a failing unit from more promising ones, or you’re splitting two promising units that need different strategies, different markets, and different management focus.
Think of it this way: a Navy engineer and a startup founder both have potential, but they need very different environments to thrive. Putting them in the same office with the same boss and the same budget doesn’t help either of them.
Why Spinoffs Create Value
Spinoffs have seven potential advantages:
But spinoffs aren’t free. There are real costs:
Chipotle / McDonald’s: Chipotle was previously owned by McDonald’s. Once it was spun off and became an independent company, its valuation experienced a significant surge and it achieved rapid growth. Different management focus, different growth strategy, different investors.
Maersk: The Danish shipping company primarily attracted coverage from shipping analysts. But it also had a substantial oil and gas exploration and production business, which would normally be covered by oil and gas analysts. After separating the two businesses, the oil and gas business started receiving analyst attention from the relevant industry experts. Academic research has also demonstrated that the quality of analyst research improved when firms underwent spinoffs.
PepsiCo / Yum! Brands: PepsiCo not only focused on selling snacks and beverages but also operated restaurants like KFC and Pizza Hut. Running fast-food restaurants presented unique challenges compared to manufacturing and distributing physical products. Eventually, PepsiCo spun off its restaurant division, which became Yum! Brands.
The synergy defense: Not everyone agrees with spinoffs. When an activist investor demanded PepsiCo separate its beverage business from its snack portfolio, Pepsi pointed out that the combination provided synergistic advantages from a shared customer base and distribution platform, leveraging the same suppliers and utilizing common brands and infrastructure globally. Sometimes the synergies are real enough to justify staying combined.
The Conglomerate Discount
Here’s the key insight: markets tend to value a diversified group of businesses at less than the sum of its parts. This is the conglomerate discount.
Why? Because analysts can’t apply the right valuation multiple to a company that does five different things. A defense company trades at different multiples than a power generation company. When they’re combined, investors don’t know which multiple to use — so they apply a blended, lower one.
Spinoffs and other forms of divestment are effective instruments to unlock these conglomerate discounts. And there’s evidence: share price reactions to divestiture announcements are typically positive.
A striking example: in March 2023, Chinese tech giant Alibaba announced its plan to split into six independently run companies — cloud and AI, domestic online shopping, international e-commerce, local services, smart logistics, and entertainment. Following the announcement, Alibaba’s US-listed shares rose 14% in a single day. Analysts thought the restructuring would allow each entity to operate under a more manageable framework, and investors could pick and choose companies that fit their own risk and reward expectations.
However, positive share price reactions don’t necessarily mean the market was wrong before. The evidence shows these reactions mostly reflect investor expectations that performance will improve once each company has the freedom to refine its strategy and deliver significant improvements in margins and growth.
Sum-of-the-Parts Valuation
To appreciate the value that might be created in a spinoff, you value each business activity separately — as if they were standalone companies. Then you add them up. This is called sum-of-the-parts (SOTP) valuation.
Yes. The 15% conglomerate discount suggests the market is penalizing the combined entity. Spinning off allows Division A to be valued on its own 20% RNOA merit, and Division B can either be turned around with focused management or acquired by someone better suited to manage it.
The key insight: management focus and capital allocation benefits often exceed the lost synergies. When Division A’s cash flow is funding Division B’s 5% RNOA projects instead of its own 20% RNOA opportunities, both divisions suffer.
Babcock & Wilcox was like a parent company with two adult children — one is a Navy engineer with a guaranteed government salary, the other is an artist trying to make it in a competitive market. Under the same roof, the engineer’s steady income subsidizes the artist’s experiments, but the engineer feels held back and the artist doesn’t get the focused attention they need.
163 Years of History
Babcock & Wilcox was one of the oldest industrial companies in America — a history stretching back to 1856. By 2014, it had grown into a classic diversified conglomerate with five business segments:
- Power Generation — boilers fired with fossil fuels (coal, oil, natural gas). A mature, declining market.
- Nuclear Operations — design and manufacturing of nuclear engine components for the US Navy. The sole provider since the 1950s.
- Technical Services — nuclear-related services for the US Department of Energy.
- Nuclear Energy — nuclear reactor equipment and services for commercial purposes.
- mPower — development of small, modular nuclear reactors for commercial energy production. B&W predicted the first mPower reactor would come online in 2018.
But at its core, it was two very different businesses under one roof: traditional power generation and a set of nuclear operations. The power side was struggling while the nuclear part was doing quite well. Two very different businesses with different end markets, customers, competitors, and growth rates — trapped under the same management structure.
The 2015 Spinoff
In 2015, Babcock & Wilcox split into two companies:
- Babcock & Wilcox Enterprises — kept the original name and the power generation business
- BWX Technologies (BWXT) — the nuclear operations business, the “crown jewel”
The nuclear business was worth a lot more than the power business. But as one combined company, investors couldn’t see that clearly.
How the Spinoff Happened: The Blue Harbour Story
The spinoff wasn’t just management’s idea. It was driven by an activist investor — a hedge fund called Blue Harbour Group.
An activist investor (most often a hedge fund) buys a significant minority stake in a company to influence its strategic direction. The fund typically identifies a way to increase value before taking a stake, then pressures the company to make changes — a merger, divestiture, management change, or other strategic move — and benefits from the resulting increase in value.
The person behind the B&W split was Robb LeMasters, then a managing director at Blue Harbour. As CEO Geveden later explained:
LeMasters described his side: “I found this very unique company called Babcock & Wilcox around the 2013 time frame. We bought a 9.9% position in Babcock & Wilcox. And in 2015, on July 1, the company effectively broke into two pieces.”
As for Geveden, he came to BWXT with an unusual background: 17 years at NASA, where he rose to Chief Engineer and then Chief Operating Officer of the entire agency, followed by 8 years at Teledyne. He wasn’t a career defense executive — he was a leader who understood how to run complex technological organizations and find new opportunities.
Why the $2.3 Billion Discount Existed
The gap between $3.7B (combined) and $6B (separate) existed for four reasons:
- Analysts couldn’t apply the right multiple. Defense companies trade at different multiples than power generation companies. Combined, analysts used a blended multiple that undervalued the nuclear business.
- Management attention was split. Running a declining power business and a growing nuclear business requires completely different strategies and leadership skills.
- Capital allocation was inefficient. Cash generated by the profitable nuclear division was partly subsidizing power generation investments that earned lower returns.
- Investor mismatch. Investors who wanted nuclear/defense exposure also had to buy struggling power generation. Those who wanted pure power generation also got nuclear. Neither group was happy.
Spinning off eliminated all four problems. As Srinivasan noted: “This is a very interesting example… the idea of sum-of-the-parts.”
The conglomerate discount. Markets penalize diversified companies because: (1) analysts can’t apply the right valuation multiple — defense multiples differ from power generation multiples, (2) management attention is split between two very different businesses, (3) capital from the profitable nuclear side may subsidize the struggling power side, and (4) investors who want nuclear exposure also have to buy struggling power generation.
Spinning off eliminates all four problems. That’s why the pieces were worth $2.3B more than the whole.
How analysts valued B&W before the split: They applied multiples-based valuation for each type of business, using different peer groups:
- Nuclear Operations & Technical Services (government customers): compared to General Dynamics, Raytheon, Lockheed Martin, and Huntington Ingalls
- Power Generation: compared to ABB, Siemens, Alstom, Fluor, and CBI Energy
Based on sum-of-the-parts, analysts projected the value at around $33 in 2014 and $36 in 2015. The stock price was exactly in this range.
Post-split stock prices (July 2015):
- BWXT: $25/share, market cap $2,688M
- B&W Enterprises: $19/share, market cap $1,017M
- Combined: $3,705M
Two years later (2017):
- BWXT: over $55/share, market cap $5,456M
- B&W Enterprises: under $12/share, market cap $529M
- Combined: $5,985M — up from $3,705M
The paradox: B&W Enterprises declined after the split — its stock fell from $19 to $12. Doesn’t that mean the spinoff failed for the power generation side?
Not necessarily. If the power generation industry experienced declines in profitability due to falling market demand, it would have impacted the original combined company regardless. The lower value of B&W Enterprises likely reflects industry trends, not the spinoff itself. What matters is that the combined value increased by $2.3 billion — shareholders who held both stocks were significantly better off.
An important analytical caution: it’s unwise to compare what happened following the split with what might have happened if the company had stayed whole. Once a company is established as a separate entity, it takes on a life of its own, influenced by market forces, managerial decisions, and industry trends.
Once free from the power generation business, BWXT could focus on what it did best: nuclear. And what a business it was.
The Core Business: Navy Nuclear Propulsion
BWXT is the sole supplier of nuclear reactors for US Navy submarines and aircraft carriers. They’ve held this position since the 1950s. This is as close to a monopoly as you get in business.
BWXT’s operations were organized into three groups:
- Nuclear Operations Group — manufactures nuclear components at facilities in Virginia and Ohio
- Nuclear Services Group — manages government-owned nuclear facilities
- Nuclear Power Group — Canadian-based, supplying fuel and replacement components for large public nuclear utilities including Ontario Power Generation and Bruce Power
The financial profile was rock-solid: strong RNOA from guaranteed government contracts, consistent free cash flow, low risk profile (defense spending is relatively recession-proof), and conservative leverage. The kind of business that prints money reliably, year after year.
But CEO Rex Geveden wasn’t hired to maintain the status quo. He was “hired to be a hunter, not a farmer.” His mandate was to find growth — to transform BWXT from a stable defense contractor into a diversified nuclear technology company.
Geveden applied a rigorous filter to evaluate which growth areas to pursue:
- High product complexity — difficult things that few companies can do
- Complex regulatory environment — creates high barriers to entry
- Very long cycle — lots of visibility into the future
- Complex materials — handling radioactive materials, specialized manufacturing
- Deep moats — businesses that discourage competitive entry
- Insensitive to global CapEx and GDP cycles — dependent on government appropriations and budgets, not on global macroeconomic conditions
As Geveden explained: “We’ve built a set of businesses that are somewhat insensitive to global CapEx and GDP cycles. For example, our naval nuclear business or these microreactors for space and national security applications with other government customers. Those are dependent upon government appropriations and budgets but not on global macroeconomic conditions.”
This filter ensured BWXT stayed in its lane: defensible businesses with long-term government or institutional customers, where nuclear expertise provides a genuine competitive advantage.
Four Growth Areas
BWXT identified four areas where its nuclear expertise could create new revenue:
Of these four, nuclear medicine was the biggest bet — and the riskiest. Geveden was candid about the risk: “Nuclear medicine might be viewed as the riskiest business and market for us to enter because it’s a couple of rings away from the bull’s-eye.”
BWXT had developed technology to produce Moly-99 using neutron capture — a method fundamentally different from the traditional approach of using a uranium target in a research reactor. The advantages: no proliferation risk and far less complex nuclear waste. To accelerate their entry, they acquired Nordion, a Canadian medical radioisotope company, for $213 million in 2018, then invested an additional $300 million on top of the acquisition — bringing the total commitment to over $500 million.
Geveden was careful to frame the scope: “This is not about drug development. Leave that to Bayer, Novartis, and all the others. But there was a niche we thought we could occupy, where we’re handling all the nuclear part on behalf of large pharma companies.” He called it “a swim lane or two away from the core business” but emphasized it was “fundamentally a nuclear materials processing business, and we know how to do that.”
BWXT’s nuclear medicine portfolio targets several key isotopes used in cancer diagnosis and treatment:
- Technetium-99m (Tc-99m) — the most widely used medical radioisotope in the world. Used in over 40 million diagnostic imaging procedures annually. BWXT aimed to become a domestic US supplier, reducing dependence on aging foreign reactors.
- Molybdenum-99 (Mo-99) — the parent isotope of Tc-99m. Production requires a nuclear reactor, making BWXT’s reactor expertise directly applicable.
- Lutetium-177 (Lu-177) — used in targeted radionuclide therapy for neuroendocrine tumors and prostate cancer. A rapidly growing market driven by new FDA-approved treatments.
- Actinium-225 (Ac-225) — an alpha-emitting isotope for next-generation targeted alpha therapy. Extremely scarce globally, with only a few facilities capable of producing it.
The strategic logic was compelling: these isotopes require specialized nuclear handling capabilities that few companies possess. BWXT’s decades of experience with nuclear materials gave it a genuine competitive advantage — not just in producing the isotopes, but in the regulatory expertise and safety infrastructure needed to manufacture and distribute them.
Beyond nuclear medicine, BWXT also pursued microreactors for the Department of Defense (portable nuclear power for remote military installations), TRISO fuel for advanced commercial reactors, and environmental remediation contracts for nuclear site cleanup. Each leveraged the company’s core nuclear competency in a different market.
Strengths:
- Market leadership — strong position and reputation in nuclear power and defense with decades of expertise
- High barriers to entry — stringent regulatory requirements, complex technologies, and specialized infrastructure
- Strategic partnerships with government agencies, providing a stable revenue stream
- Diversified product portfolio — migrating from focused nuclear reactor provider to multi-product firm
- Compliance and control culture — essential in nuclear businesses
- Innovation culture — Geveden wanted to pursue new avenues of growth beyond the core
- Strong financial performance — track record of consistent returns from guaranteed contracts
Challenges:
- Regulatory risks — compliance costs and uncertainties could increase operating costs and affect profitability
- Operational risks — nuclear businesses carry constant risk (leaks, material escapes)
- Highly concentrated customer base — US government agencies represent 80% of BWXT’s customers, posing a risk if contracts aren’t renewed
- Limited growth from compliance culture — the culture of compliance and control may dampen the creativity and innovation needed for new markets
- Lack of medical industry knowledge — the medical market is highly specialized, and BWXT leadership lacked experience in this field
- Organizational challenges — with over two-thirds of the company focused on nuclear operations, the nuclear medical division may lack attention and resources
It depends on your investment thesis. The Navy business is a cash machine, but it has limited growth — defense budgets grow slowly. If you invested in BWXT for stability, you might prefer dividends and buybacks. If you see BWXT’s nuclear expertise as transferable to medicine, the $500M bet could transform the company.
The key question: does BWXT’s nuclear competency give it a genuine competitive advantage in medicine, or is this diversification for its own sake? Building nuclear reactors for the Navy and producing medical isotopes both require nuclear expertise — but they’re very different markets with different customers, regulatory environments, and competitive dynamics.
This is exactly the kind of debate that played out among BWXT’s investors — and it’s why the stock stagnated for three years.
Imagine you’re a surgeon with a guaranteed hospital salary of $500K per year. Someone offers you a chance to invest your savings in a medical startup that could 10x your money — but it could also go to zero. You’d still keep your salary either way.
That’s BWXT’s dilemma. The core Navy business pays the bills no matter what. But the nuclear medicine bet requires capital that could otherwise go back to shareholders.
The Capital Allocation Dilemma
BWXT generates strong free cash flow from the Navy business. The question: what do you do with it? There were three options:
Geveden chose option 2 — invest in growth. The projected numbers looked attractive: $200M+ in annual revenue once at scale, with 30%+ EBIT margins. But there were years until profitability, regulatory hurdles, and a competitive landscape to navigate.
Geveden’s Risk Assessment
Geveden was systematic about evaluating risk. He saw it as proportional to how far from the core business you’re reaching:
“When you think about going from naval nuclear propulsion into microreactors, that’s a pretty natural sidestep for us. The most challenging risk there has to do with project execution if it’s a first of a kind.”
Nuclear medicine was different: “I would say that nuclear medicine might be viewed as the riskiest business and market for us to enter because it’s a couple of rings away from the bull’s-eye. It does have a different set of competitors and slightly different regulatory context. And obviously, the way you treat it financially is you just discount it more heavily.”
He described a rigorous pressure-testing process: “You have to ask these hard questions: you believe you’re going to get 30% of the market, but have you evaluated how the competitors are going to react, and what that’s going to do with the pricing structure? Do we have the institutional wherewithal? Do we have the right kind of expertise? The right kind of systems? The right kind of management?”
The Analyst’s Perspective: Peter Arment
Peter Arment, Senior Aerospace Defense Analyst and Managing Director at Baird (a privately held global investment bank with ~6,000 employees), had been covering BWXT for years. He provided the analyst’s perspective on the nuclear medicine bet.
Arment laid out the investment details: BWXT acquired Nordion for $213 million in 2018 — “a small medical isotope business that was being kind of on its stand-alone in a private equity portfolio in Canada. It was not being invested in.” Then came $300 million more on top. By 2022, they were just submitting their FDA application for Moly-99 — “There’s been a couple years of delays along the way. They thought they could commercialize the product within two years.”
Arment framed the dilemma with a bull case and a bear case:
- Bull case: BWXT captures 40% market share in North America, generates over $100M in revenue from high-margin medical isotopes. Core business margins in the high teens; medical isotope margins are double that. This adds enormous value.
- Bear case: FDA application process goes longer, market share ramp takes longer, margins don’t achieve projections — and the returns on a half-billion dollars of shareholder money aren’t there.
His summary captured the tension perfectly: “When we look at it in 2022, you have a crown jewel business that’s being a little bit diluted by its pursuits for growth. If they never pursued nuclear medicine, they would be executing on their core quite well. But most CEOs want to grow. And so they’re always looking for adjacencies or M&A opportunities.”
Why Analysts Panicked
Here’s the problem: aerospace and defense analysts cover BWXT. They understand Navy contracts, defense budgets, and submarine procurement cycles. They do not understand healthcare, nuclear medicine, FDA approvals, or radioisotope markets.
The nuclear medicine investment dragged near-term margins and free cash flow. Analysts saw spending go up and returns go down. Some reduced their price targets. The stock stagnated at the $40–50 range from 2021 to 2023.
As Geveden explained: “In our particular case, we’re covered by aerospace and defense analysts. And then you bring in this new variable of, say, nuclear medicine… And it’s a little bit unfamiliar. And so I’d say the lack of familiarity creates some uncertainty with analysts, and therefore with investors.”
Arment described the investor exodus: before nuclear medicine, BWXT had a 30–40% premium multiple to its defense peers because it was a pure play with extraordinary visibility. Investing in medical isotopes “diluted the story, and it also diluted the multiple.” Between 2018 and 2022, there was an ownership change in the stock — institutional investors who had bought it as a pure-play nuclear/defense story sold because they didn’t understand (or want exposure to) medical isotopes.
The business model — open book contracting:
Arment explained BWXT’s unique economics: “They have open book contracting with the Department of Defense and the Department of Energy. The government will give you a 15% fixed fee on your cost base. That’s about a 13% fee on your revenues.” Through labor productivity improvements, BWXT pushed actual operating margins into the high teens. And they had room to negotiate: “They probably can have a negotiation with their government customer to raise their fixed fee. Maybe instead of 15%, it could go to 17.”
Building a single Columbia-class submarine reactor takes an 8-year build cycle — enormous CapEx requirements but enormous visibility into future revenue.
CFO LeMasters on strategy and finance:
“I think that strategy is only successful if it’s grounded in financial analysis. If you’re good at moving the different chess pieces around and knowing the scenarios, but then mapping that to how that will actually translate into financial success and ultimately to a Wall Street perspective of how people might value you, then you have a unique combination where you’re not only thinking strategically, but you’re thinking about financially being strategic.”
DuPont analysis (2016–2020):
- Sales growth: consistently positive, above 5% annually (most recent: 12.1% in 2020)
- NOPAT margins: stable at ~14%, indicating steady-state core business
- Net operating asset turnover: declining from 3.26 to 1.6 — BWXT’s ability to generate sales per dollar of assets was weakening
- RNOA: declined, largely driven by the declining asset turnover
- ROE: high but declining — from 85.2% (2016) to 54.5% (2020)
- 2018 anomaly: sharp increase in net financial leverage as BWXT doubled its long-term debt and stopped stock repurchases to fund nuclear medicine
Professor Yuan Zou noted that BWXT’s margins were higher than the industry average for the past five years, but “the upside potential is a question.” The nuclear medicine entry in 2018 showed a decrease in gross margin and EBITDA margin from the setup costs.
Valuation assumptions for ~$50 price:
A valuation model yielding $50.92/share required these assumptions:
- Sales growth at 2% (vs. historical average of 8%)
- NOPAT/Sales at 13% (matching historical)
- Net Working Capital/Sales at 13.5% (vs. historical 8%)
- Net Operating LT Assets/Sales at 58% (vs. historical 31%)
- Net Debt/Total Capital at 59% (matching historical)
The most telling assumption: 2% sales growth vs. historical 8%. The market at $50 was pricing in barely any growth beyond inflation — essentially zero value for all of BWXT’s growth investments.
As Charis Ji, a public markets investor, explained the approach: “In the public market, you know the price. The idea is to work backwards and figure out what you need to believe in order to generate your required returns. When a company is trading at low valuations, perhaps you only need one or two things to improve in order to make money.”
“What’s in the Price?”
There’s a powerful analytical technique for situations like this: “what’s in the price” analysis. Instead of valuing the company from scratch, you reverse-engineer what assumptions the current stock price implies.
Here’s how it works:
- Take the current stock price
- Reverse-engineer the growth rate, margin, and capital efficiency assumptions that the price implies
- Compare those implied assumptions to your own analysis
- If the market’s assumptions are too pessimistic → undervalued. Too optimistic → overvalued.
For BWXT at $45: the price implied about 2–3% long-term growth — essentially just the Navy business with inflation adjustments (vs. a historical average of 8%). The market was pricing in almost no value for nuclear medicine. A $500M+ investment was being valued at close to zero.
Valuing the nuclear medicine piece was especially tricky because there weren’t many publicly traded comparables — Arment noted that in 2022, NuScale was public while X-energy and Terra were private. So analysts used a combination of DCF for the core business (with its excellent visibility) and a separate sum-of-the-parts estimate for nuclear medicine using medical isotope space multiples.
If you believed nuclear medicine would succeed — even partially — the stock was undervalued. If you thought it was a money pit, the price was about right. That’s the power of “what’s in the price” — it turns a valuation question into a question about your own beliefs.
“By analyzing the assumptions and expectations that are reflected in the current price, we can better assess whether the company is over- or undervalued.” If the forecast assumptions are too optimistic, the company is probably overvalued. If too pessimistic, the price is low and the company is probably undervalued.
If you believe nuclear medicine will succeed, the stock is undervalued. The market is pricing in almost no value for a $500M+ investment. Even if nuclear medicine achieves only half its projected $200M revenue at 30% EBIT margins, that’s $30M additional annual operating income — worth several hundred million at reasonable multiples.
The risk: the market might be right that nuclear medicine won’t pan out. This is “what’s in the price” analysis — identifying the gap between what the market assumes and what you believe. The investment decision depends on your conviction about BWXT’s ability to execute in a new market.
Imagine you’re a startup founder pitching to VCs, but your pitch deck shows a safe government contract instead of a hockey-stick growth chart. The VCs don’t know how to value you — you’re not a typical defense company and you’re not a typical biotech. You’re stuck in no-man’s-land.
That was BWXT’s challenge: defense analysts couldn’t value the nuclear medicine opportunity, and healthcare investors didn’t know BWXT existed.
The Information Asymmetry Problem
The core issue was information asymmetry — managers know more about their business than outside investors. This is a concept we discussed at the very beginning of this series (Post 1), and here it shows up again in full force.
CFO LeMasters explained it directly:
The second challenge: BWXT was pursuing new markets, and new markets are unfamiliar to analysts. LeMasters noted: “Investors want to invest in a theme and a cohesive story; that’s difficult to articulate in new, risky markets. And when we look at the plethora of opportunities, and try to value it… we say, wow, these are all going to be quite valuable, whereas investors haven’t even seen these.”
Four Ways Companies Communicate with Investors
There are four standard methods for bridging the information gap between management and investors:
Companies cannot selectively disclose material nonpublic information to certain investors. If you tell one investor something material, you must disclose it to everyone simultaneously. This prevents insider advantages but limits the depth of private conversations.
An important caveat from Professor Yuan Zou: sum-of-the-parts analysis is only practical if it’s actionable — meaning the company actually intends to spin off or sell the divisions. You can’t just calculate a theoretical SOTP value and claim the stock is undervalued unless there’s a plausible path to unlocking that value.
What BWXT Actually Did
BWXT’s management went beyond standard investor relations. Here’s their playbook:
1. Increased communications tempo. Geveden was emphatic about this:
2. Episodic buybacks. When the stock dipped, BWXT used its own cash to buy shares — signaling that management believed the intrinsic value was higher than the market price:
LeMasters framed buybacks brilliantly:
3. Hit milestones. Ultimately, communication only goes so far. The company had to deliver. As Geveden put it: “In the end, we have to succeed with these investments… we have to prove that the risks that we took are worth taking by seeing an inflection point in our return on invested capital, seeing an inflection point in cash and cash flow, seeing us win a number of these competitive opportunities.”
Three Ways to Bridge the Price-Value Gap
BWXT’s experience illustrates three methods any company can use when the market price doesn’t reflect intrinsic value:
- Better communication — educate analysts about new markets, provide milestones, build trust through transparency. If investors don’t understand the story, they can’t value it correctly.
- Hit milestones — talking only gets you so far. Hitting operational milestones proves the strategy is working and builds trust with actions, not just words.
- Stock buybacks — signals management confidence. But there’s a trade-off: capital used for buybacks can’t fund growth investments. It reduces financial flexibility and cash reserves. BWXT resolved this by being episodic — buying on dips rather than running a continuous buyback program.
On why the stock was undervalued:
LeMasters: “When I look at this company, we’re very convinced that we’re onto something very big here. But our stock price isn’t reflecting that. And so we need to look at ourselves and say, why is that? What can we do different? And so we’re trying to educate people about how we have these unique core businesses. And we do something very special in the world.”
On planting seeds for growth:
LeMasters: “And we’ve also planted the seeds to be a diversified growth company within the nuclear space. And educating our shareholders and bringing that value to bear, because we’re proud of it, and we know there are certain shareholders that own our stock for it, we want to make sure that that’s properly valued and that our employees are benefiting from that, our board’s benefiting from that, our shareholders are benefiting from that. And as the CFO, that really is something that I focus on every day is making the most of what we’ve already planted the seeds for.”
On information asymmetry:
LeMasters identified three reasons the stock was undervalued relative to intrinsic value:
- Information asymmetry — managers know more than investors. Relationships being formed behind the scenes couldn’t be publicly disclosed yet.
- Unfamiliar markets — investors want to invest in a “theme and a cohesive story.” New, risky markets are hard to articulate. Investors hadn’t even seen many of the opportunities BWXT was pursuing.
- Signaling through buybacks — LeMasters: “If we believe that the intrinsic value is so disconnected from the price, then why don’t we use our own capital to buy more of ourselves” — this is the strongest signal management can send.
On buyback trade-offs:
Buybacks involve opportunity cost — capital used for buybacks can’t fund growth investments. They also reduce financial flexibility and cash reserves. But they signal confidence: “When they see us jumping in at the right price point… it makes sense.” BWXT balanced this by investing in nuclear medicine and doing episodic buybacks on dips — not choosing one over the other.
On proving it works:
Geveden: “We spent a lot of time with investors trying to talk through the characteristics of the new businesses, and how they’re not really that far from our core business. But it is a challenge to try to build off of a core business that’s as attractive as this one is.”
The full communication toolkit:
Beyond the three methods above, the course identified four specific actions a CEO or CFO can take:
- Increase frequency and transparency — additional investor presentations, industry conferences, one-on-one meetings with key investors to address misconceptions
- Emphasize mission and strategy — clearly articulate how new markets fit within the broader strategic framework
- Highlight industry opportunity and unique strengths — nuclear medicine may be unfamiliar to many investors, so educating them is essential. Engage key opinion leaders in the field (physicians, researchers, healthcare professionals) to endorse and validate the company’s offerings
- Provide strategic guidance and updates — specific initiatives, operational milestones, and market opportunities that give investors a roadmap for future success
Split between both. Investing entirely in nuclear medicine ignores the signaling value of buybacks and risks overinvesting in an uncertain market. But buying back only stock ignores the growth opportunity.
The split signals confidence (buybacks), funds growth (nuclear medicine investment), and maintains optionality. This is exactly what BWXT did — “episodic buybacks” during price dips while continuing to invest in growth.
Dividends are the weakest option here because they don’t signal undervaluation and would shift BWXT’s investor base from growth-seekers to income-seekers. Switching to a regular dividend policy alters the company’s investment profile — investors seeking growth stocks may leave, while income-seekers arrive. The impact on valuation is unclear.
Two other options to rule out: issuing new stock would increase shares outstanding and dilute per-share value — the opposite of what you want when undervalued. A stock split wouldn’t alter intrinsic value at all — it just splits existing value into smaller pieces.
Remember: BWXT’s stock was stuck at $40–50 for three years while management invested in nuclear medicine and tried to convince skeptical analysts. Then…
What Drove the Recovery?
Multiple factors converged:
- Nuclear medicine milestones started being hit. The investments began producing tangible results — regulatory progress, customer wins, and revenue ramp-up.
- Defense spending increased. Geopolitical tensions (Ukraine, Taiwan) boosted defense budgets, directly benefiting BWXT’s core Navy business.
- Market recognition. Analysts finally understood that BWXT’s nuclear expertise had genuine commercial applications beyond defense.
- Communication worked. Years of increased transparency, investor days, and episodic buybacks had gradually built trust with the investment community.
LeMasters had said: “When I look at this company, we’re very convinced that we’re onto something very big here. But our stock price isn’t reflecting that.”
By late 2025, the stock price finally reflected it.
Both factors contributed. Defense spending increased significantly due to geopolitical tensions, which boosted the core Navy business. But the nuclear medicine investments also started hitting milestones, validating the growth thesis.
The complete answer: Geveden was right that the stock was undervalued and right that nuclear medicine would pay off — but the defense spending tailwind provided the initial catalyst that brought investors back to the stock, and the nuclear medicine progress provided the additional upside that pushed it from “fairly valued” to “tripled.”
This is why “what’s in the price” analysis is so powerful. At $45, you were getting the growth option almost for free. The defense tailwind alone justified a higher price, and nuclear medicine was pure bonus.
BWXT’s story is the capstone of this entire series. Every concept we’ve learned in 10 posts shows up in this one company.
How Each Post Connects to BWXT
Spinoffs as the Inverse of M&A
Here’s the key insight that ties this series together:
- In M&A (Posts 8–9), the thesis is: combined > separate. Synergies create value. Thermo Fisher paid $17.4B because PPD + Thermo Fisher > PPD alone + Thermo Fisher alone.
- In spinoffs (this post), the thesis is: separate > combined. The conglomerate discount destroys value. B&W’s pieces were worth more apart because the nuclear business was being held back by the power business.
There’s no universal answer about which is better. It depends on whether the synergies of being combined exceed the costs — the management distraction, capital misallocation, and analyst confusion that come with diversification.
Separate > Combined? → Spin Off
The “What’s in the Price” Methodology
One of the most valuable tools from this module is the “what’s in the price” framework. Here’s the complete methodology:
- Take the current stock price. This is the market’s consensus about the company’s future.
- Reverse-engineer the assumptions. What growth rate, margin, and capital efficiency does the price imply? Use a DCF model in reverse.
- Compare to your analysis. Are the implied assumptions too optimistic? Too pessimistic? Reasonable?
- Identify the gap. If the market assumes 3% growth but you believe 8% is achievable → the stock is undervalued. If the market assumes 15% growth but you see evidence of slowing → overvalued.
As Srinivasan noted: “For analysts and investors, developing a strong capability to analyze a company undergoing transformation is very important. This is a chance to differentiate yourself in a context where there is a great deal of uncertainty.”
Step 1: Identify distinct business units. Which divisions have genuinely different growth profiles, customer bases, competitive dynamics, and risk profiles? If two divisions serve the same customers with similar margins, they may not need to be separated.
Step 2: Value each unit separately. Use the method most appropriate for each:
- Stable, mature businesses → comparable company multiples (EV/EBITDA, P/E)
- Growing businesses → DCF with appropriate growth assumptions
- Declining businesses → liquidation value or distressed comparables
Step 3: Sum the values. Add up all individual division values. This is the sum-of-the-parts value.
Step 4: Compare to market cap. If SOTP > market cap, a conglomerate discount exists. The bigger the gap, the stronger the case for a spinoff.
Step 5: Assess the discount. Not all conglomerate discounts should be unlocked. Consider:
- Are there real synergies between divisions that would be lost?
- Will separated companies have sufficient scale to attract analyst coverage?
- Are there shared capabilities (R&D, distribution, brand) that create genuine value together?
- Will management teams be strong enough to run independent companies?
Step 6: Make the recommendation. If the discount exceeds the value of synergies and shared capabilities, a spinoff creates value. If synergies are substantial, the company should remain combined and work to better communicate the value of each division to analysts.
Spin off or sell Division C immediately — it’s declining and diluting the valuation multiple. Then consider spinning off Division A — at 25x multiples for comparables, it’s being valued at only 10x as part of the conglomerate. That’s a massive conglomerate discount.
Sum-of-parts reveals the company is worth significantly more as pieces. If A earns $100M, B earns $50M, and C earns $30M, the SOTP value would be ($100M × 25) + ($50M × 8) + ($30M × 4) = $2.5B + $400M + $120M = $3.02B. But at 10x combined earnings of $180M, the market values it at only $1.8B. That’s a 40% conglomerate discount.
This is exactly the logic behind the B&W spinoff — the nuclear division (like A) was being dragged down by the power division (like C).
Professor Srinivasan’s closing words for the course:
The 10-Post Journey
Here’s what we’ve covered — from reading financial statements to valuing entire companies:
- Strategy lives in the numbers (NVIDIA vs Intel vs TSMC) — financial statements aren’t just accounting; they reveal a company’s strategic choices.
- Transitions show up in financials (Netflix’s three reinventions) — when a company transforms, the numbers change before the narrative does.
- ROE decomposition reveals the engine (DuPont breakdown) — is it margins, efficiency, or leverage driving returns?
- Separate operations from financing (Modified DuPont, RNOA, FCF) — the X-ray machine that shows what a business really earns from its operations.
- Forecast the future systematically (6-step framework, Intel IDM 2.0) — from revenue growth to cost of debt, a complete forecasting toolkit.
- Value a company from scratch (DCF, terminal values) — discounted cash flow valuation, the gold standard.
- Three pricing methods and when each fails (AEM, multiples, ADI) — abnormal earnings, comparable multiples, and the ADI case where all three methods converged.
- Why companies pay billions for synergies (M&A playbook, Thermo Fisher) — the logic, the math, and the risks of acquisitions.
- Was the $17.4B bet worth it? (PPD valuation & verdict) — from valuation to negotiation to the 2.5-year scoreboard.
- When breaking apart creates more value (BWXT spinoff & transformation) — spinoffs, sum-of-parts, and the art of investor communication.
The Meta-Lesson
If there’s one sentence that captures everything:
What started with “how to read a company’s strategy from its numbers” ends with a company that created billions by breaking apart, investing in transformation, and communicating its vision to skeptical investors. The tools are the same throughout — strategy analysis, ratio decomposition, forecasting, valuation. The applications are infinite.
A company has two divisions: Tech (40% EBIT margins, growing 20%) and Manufacturing (8% margins, growing 2%). Tech comparables trade at 30x earnings, Manufacturing at 8x. Tech earns $200M, Manufacturing earns $100M. The combined company trades at 15x combined earnings ($300M × 15 = $4.5B).
What’s the sum-of-parts value? What’s the conglomerate discount?
Sum-of-the-parts: ($200M × 30) + ($100M × 8) = $6B + $800M = $6.8B.
Conglomerate discount: ($6.8B − $4.5B) / $6.8B = 33.8%.
The Tech division alone ($6B) is worth more than the entire combined company ($4.5B). Manufacturing is actually destroying value in this structure — not because it’s a bad business, but because it drags the combined multiple from 30x down to 15x.
Spinning off Tech would immediately unlock $1.5B+ in value. This is the same math that drove the B&W spinoff.
BWXT trades at $45/share with 100M shares outstanding ($4.5B market cap). The core Navy business generates $400M NOPAT at 12% RNOA. Nuclear medicine currently loses $50M/year but is projected to earn $60M/year in 5 years.
Using a simple perpetuity at 10% discount, what’s the Navy business worth alone? What does the $45 price imply about nuclear medicine’s value?
Navy business value: $400M / 0.10 = $4.0B.
Market cap: $4.5B. Implied nuclear medicine value: $4.5B − $4.0B = $500M.
But nuclear medicine is currently losing money ($50M/year) and requires $500M+ in planned investment. The $45 price is essentially giving nuclear medicine minimal credit for future value — you’re getting the growth option almost for free.
If nuclear medicine achieves its projections ($60M/year at 10% discount = $600M), plus the Navy business grows at all, the company should be worth significantly more than $4.5B. This is why “what’s in the price” analysis is so powerful — it reveals what the market is assuming about the future, and you can decide whether those assumptions are too pessimistic.
You’re BWXT’s CEO. Your stock dropped 15% after an analyst downgrade. The analyst says: “Nuclear medicine investments are diluting returns with uncertain payoff.” You have a quarterly earnings call in 2 weeks.
What’s your communication strategy?
Geveden’s actual playbook, applied:
- Provide specific milestones and timelines for nuclear medicine — regulatory approvals expected, revenue targets, customer pipeline. Convert “uncertain payoff” into measurable, trackable progress.
- Announce a targeted buyback program to signal confidence. “If we believe the intrinsic value is disconnected from the price, then why don’t we use our own capital to buy more of ourselves?”
- Offer a dedicated nuclear medicine briefing for analysts. Defense analysts don’t understand healthcare — educate them rather than hoping they’ll figure it out.
- Emphasize that the Navy business alone justifies the current stock price — nuclear medicine is pure upside. Frame the investment as optionality, not dilution.
- Compare investment returns to core business over a 5–7 year horizon. Short-term margin compression is the cost of long-term transformation.
Key principle: Address the analyst’s concern directly with data, not just narrative. “You can’t communicate enough in a case like this.”
A $15B conglomerate has four divisions: Cloud (45% margins, 25% growth), Enterprise Software (30% margins, 8% growth), Hardware (12% margins, −2% growth), and Consulting (20% margins, 5% growth). Analysts complain they can’t value it.
Which division(s) should be spun off? Why?
Spin off Hardware first — it’s declining (negative growth) and dragging the blended valuation multiple. Hardware at 12% margins with −2% growth deserves maybe 6–8x earnings. But it’s pulling the whole company’s multiple down.
Then consider spinning off Cloud — its 25% growth rate and 45% margins deserve a premium multiple (30–40x or higher). As part of the conglomerate, Cloud is being valued at whatever blended multiple analysts assign to the whole — probably 15–18x. That’s a massive undervaluation.
Keep Enterprise Software + Consulting together — they make a coherent “business solutions” story with similar growth profiles and customer bases. Analysts can understand and value this combination easily.
Key principle: Spin off divisions that (a) have very different growth profiles from the core, or (b) are declining and diluting the overall story. Keep together divisions that share customers, growth profiles, or strategic synergies.